DrugPatentWatch Database Preview

Flortaucipir f-18 - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for flortaucipir f-18 and what is the scope of patent protection?

Flortaucipir f-18 is the generic ingredient in one branded drug marketed by Avid Radiopharms Inc and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Flortaucipir f-18 has eighteen patent family members in nine countries.

One supplier is listed for this compound.

Summary for flortaucipir f-18

International Patents:	18
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	9
Patent Applications:	7
What excipients (inactive ingredients) are in flortaucipir f-18?	flortaucipir f-18 excipients list
DailyMed Link:	flortaucipir f-18 at DailyMed

Recent Clinical Trials for flortaucipir f-18

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Neil M Rofsky, MD, MHA	Phase 2
Avid Radiopharmaceuticals	Phase 3
Avid Radiopharmaceuticals	Phase 2

See all flortaucipir f-18 clinical trials

US Patents and Regulatory Information for flortaucipir f-18

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-002	May 28, 2020		RX	Yes	Yes
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-001	May 28, 2020		RX	Yes	Yes				Y
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-002	May 28, 2020		RX	Yes	Yes				Y
Avid Radiopharms Inc	TAUVID	flortaucipir f-18	SOLUTION;INTRAVENOUS	212123-001	May 28, 2020		RX	Yes	Yes

International Patents for flortaucipir f-18

Country	Patent Number	Estimated Expiration
Spain	2792830
Canada	2873963
Australia	2012381042
South Korea	20100135235
Japan	2011512354